Article Dans Une Revue Bioconjugate Chemistry Année : 2019

Antibody Pretargeting Based on Bioorthogonal Click Chemistry for Cancer Imaging and Targeted Radionuclide Therapy

Résumé

Bioorthogonal click chemistry-employing antibody-conjugated trans-cyclooctenes (TCO) and tetrazine (Tz)-based radioligands able to covalently bind in vivo-appeared recently as a potential alternative to circumvent the hematotoxicity induced by radioimmunotherapy of solid tumors. This Review focuses on the recent advances concerning TCO/Tz pretargeting in both cancer imaging and targeted-radionuclide therapy for prospective clinical transfer. We exhaustively identified 25 PubMed publications reporting preclinical imaging and 5 therapy studies with full mAbs as targeting vectors, since its first application in 2010. The fast, safe, modulable, and specific TCO/Tz pretargeting showed high potential as a theranostic tool to get more personalized and precise cancer care. The recent optimizations reported here highlighted a possible first clinical evaluation of IEDDA pretargeting in the coming years.

Fichier non déposé

Dates et versions

hal-02887982 , version 1 (02-07-2020)

Identifiants

Citer

Aurélie Rondon, Françoise F. Degoul. Antibody Pretargeting Based on Bioorthogonal Click Chemistry for Cancer Imaging and Targeted Radionuclide Therapy. Bioconjugate Chemistry, 2019, 31 (2), pp.159-173. ⟨10.1021/acs.bioconjchem.9b00761⟩. ⟨hal-02887982⟩
66 Consultations
0 Téléchargements

Altmetric

Partager

  • More